AR025459A1 - Antagonistas muscarinicos - Google Patents
Antagonistas muscarinicosInfo
- Publication number
- AR025459A1 AR025459A1 ARP000104540A ARP000104540A AR025459A1 AR 025459 A1 AR025459 A1 AR 025459A1 AR P000104540 A ARP000104540 A AR P000104540A AR P000104540 A ARP000104540 A AR P000104540A AR 025459 A1 AR025459 A1 AR 025459A1
- Authority
- AR
- Argentina
- Prior art keywords
- muscarinic antagonists
- alkoxy
- halogen
- alkyl
- substituents selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40139199A | 1999-09-22 | 1999-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025459A1 true AR025459A1 (es) | 2002-11-27 |
Family
ID=23587566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104540A AR025459A1 (es) | 1999-09-22 | 2000-08-31 | Antagonistas muscarinicos |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1214299B1 (enExample) |
| JP (1) | JP2003509494A (enExample) |
| CN (1) | CN1167682C (enExample) |
| AR (1) | AR025459A1 (enExample) |
| AT (1) | ATE264301T1 (enExample) |
| AU (1) | AU5786300A (enExample) |
| CA (1) | CA2384018C (enExample) |
| CO (1) | CO5180624A1 (enExample) |
| DE (1) | DE60009931T2 (enExample) |
| ES (1) | ES2215055T3 (enExample) |
| HK (1) | HK1043590A1 (enExample) |
| MX (1) | MXPA02003136A (enExample) |
| PE (1) | PE20010649A1 (enExample) |
| WO (1) | WO2001021590A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| CN1301972C (zh) * | 2001-10-10 | 2007-02-28 | 先灵公司 | 作为毒覃碱拮抗剂的哌啶化合物 |
| JPWO2004069828A1 (ja) * | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| HK1253029A1 (zh) | 2015-11-06 | 2019-06-06 | Neurocrine Biosciences, Inc. | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| DE69919171T2 (de) * | 1998-06-30 | 2005-08-04 | Schering Corp. | Muskarin-rezeptor antagonisten |
| US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
-
2000
- 2000-07-05 ES ES00943386T patent/ES2215055T3/es not_active Expired - Lifetime
- 2000-07-05 WO PCT/US2000/018358 patent/WO2001021590A1/en not_active Ceased
- 2000-07-05 HK HK02105117.5A patent/HK1043590A1/zh unknown
- 2000-07-05 DE DE60009931T patent/DE60009931T2/de not_active Expired - Lifetime
- 2000-07-05 CA CA002384018A patent/CA2384018C/en not_active Expired - Fee Related
- 2000-07-05 JP JP2001524970A patent/JP2003509494A/ja active Pending
- 2000-07-05 AT AT00943386T patent/ATE264301T1/de not_active IP Right Cessation
- 2000-07-05 AU AU57863/00A patent/AU5786300A/en not_active Abandoned
- 2000-07-05 CN CNB008130795A patent/CN1167682C/zh not_active Expired - Fee Related
- 2000-07-05 MX MXPA02003136A patent/MXPA02003136A/es unknown
- 2000-07-05 EP EP00943386A patent/EP1214299B1/en not_active Expired - Lifetime
- 2000-08-31 PE PE2000000890A patent/PE20010649A1/es not_active Application Discontinuation
- 2000-08-31 AR ARP000104540A patent/AR025459A1/es unknown
- 2000-08-31 CO CO00065610A patent/CO5180624A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2384018A1 (en) | 2001-03-29 |
| HK1043590A1 (zh) | 2002-09-20 |
| ES2215055T3 (es) | 2004-10-01 |
| AU5786300A (en) | 2001-04-24 |
| JP2003509494A (ja) | 2003-03-11 |
| EP1214299B1 (en) | 2004-04-14 |
| DE60009931T2 (de) | 2005-04-07 |
| DE60009931D1 (de) | 2004-05-19 |
| CN1374949A (zh) | 2002-10-16 |
| CA2384018C (en) | 2010-01-12 |
| ATE264301T1 (de) | 2004-04-15 |
| CN1167682C (zh) | 2004-09-22 |
| PE20010649A1 (es) | 2001-06-19 |
| WO2001021590A1 (en) | 2001-03-29 |
| CO5180624A1 (es) | 2002-07-30 |
| EP1214299A1 (en) | 2002-06-19 |
| MXPA02003136A (es) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY133992A (en) | Muscarinic antagonists | |
| CN100415716C (zh) | 1-(1,2-双取代哌啶基)-4-取代哌嗪衍生物 | |
| AU597188B2 (en) | 2-{(4-piperidyl)methyl}-1,2,3,4-tetrahydro-9h-pyrido{3,4-b }indole derivatives, their preparation and their application in therapy | |
| NO20061419L (no) | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser | |
| NO990551L (no) | Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister | |
| NO990671D0 (no) | Muskarinantagonistiske etere | |
| AR025459A1 (es) | Antagonistas muscarinicos | |
| NO20005166L (no) | Nye benzotiofen-, benzofuran- og indolforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| PE20040687A1 (es) | Quinolinas sustituidas como antagonistas del receptor ccr5 | |
| JPWO2006046552A1 (ja) | 新規な含窒素複素環化合物およびその塩 | |
| RU2005114489A (ru) | N-акрил-4-метиленамино-3-гидрокси-2-пиридоны в качестве противомикробных препаратов | |
| RU2004130426A (ru) | Циклические амиды | |
| AR043501A1 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| AR019167A1 (es) | Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos | |
| YU40998A (sh) | Derivati supstituisanog 1,2,3,4-tetrahidronaftalina | |
| JP2024020453A (ja) | Rock阻害剤としての重水素化合物 | |
| US2846437A (en) | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof | |
| SE9703377D0 (sv) | New compounds | |
| NZ333513A (en) | 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists | |
| DE3878371T2 (de) | Psychotropische bizyklische imide. | |
| DE3875866T2 (de) | Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie. | |
| KR960022486A (ko) | 신규 티아졸리딘-4-온 유도체 | |
| DE60105610D1 (en) | Pyrazinonderivate | |
| FI942976A0 (fi) | 5-amino-8-metyyli-7-pyrrolidinyylikinoliini-3-karboksyylihappojohdannaiset | |
| CA2076146A1 (en) | Piperidine derivatives |